You have 9 free searches left this month | to do more
Showing 1 - 25 of
662 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Molecular Biology of Polycythemia and Thrombocytosis
Recruiting
  • Polycythemia
  • Thrombocytosis
    • Salt Lake City, Utah
      University of Utah
    2021-10-29
    Oct 29, 2021
    M
    Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
    Recruiting
    • Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
    • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    2022-01-19
    Jan 19, 2022
    M
    LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
    Active, not recruiting
    • Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
    • +2 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    2021-11-08
    Nov 8, 2021
    U
    Arterial Function and Atherosclerosis in Essential Thrombocythemia - 2021
    Completed
    Has Results
    • Atherosclerosis
    • imaging
    • (no location specified)
    2021-10-06
    Oct 6, 2021
    T
    Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
    Recruiting
    • Thrombocythemia, Essential
    • San Antonio, Texas
      Mays Cancer Center
    2021-12-14
    Dec 14, 2021
    N
    A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
    Active, not recruiting
    • Primary Myelofibrosis
    • +2 more
    • Jakavi
    • Aachen, Germany
      Novartis Investigative Site
    2021-09-06
    Sep 6, 2021
    N
    MAP to Provide Access to Ruxolitinib, for Patients With PMF or PPV MF or PET-MF
    Available
    • Primary Myelofibrosis (PMF)
    • +2 more
    • (no location specified)
    2022-01-18
    Jan 18, 2022
    I
    Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
    Recruiting
    • Essential Thrombocytopenia
    • Recombinant Interferon Alpha
    • Pegylated interferon alfa-2b
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    2022-03-25
    Mar 25, 2022
    U
    An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
    Active, not recruiting
    • Myeloproliferative Neoplasm
    • +4 more
    • Orange, California
      Chao Family Comprehensive Cancer Center, University of Californi
    2022-01-20
    Jan 20, 2022
    M
    Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
    Not yet recruiting
    • Myelofibrosis
    • +2 more
    • Peptide-based vaccine
    • Poly ICLC
    • New York, New York
      Icahn School of Medicine at Mount Sinai
    2021-08-24
    Aug 24, 2021
    I
    Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms
    Recruiting
    • Thrombocythemia, Essential
    • Primary Myelofibrosis
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    2022-01-24
    Jan 24, 2022
    T
    IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
    Recruiting
    • Essential Thrombocythemia
    • Polycythemia Vera
    • Miami, Florida
      University of Miami
    2021-09-23
    Sep 23, 2021
    U
    Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
    Recruiting
    • Primary Myelofibrosis
    • +2 more
    • Salt Lake City, Utah
      Huntsman Cancer Institute/University of Utah
    2021-09-27
    Sep 27, 2021
    S
    Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
    Recruiting
    • Myelofibrosis
    • +3 more
    • Jaktinib hydrochloride tablets
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital of Medical School of Zhejiang Univ
    2021-06-11
    Jun 11, 2021
    N
    Study of Select Combinations in Adults With Myelofibrosis
    Withdrawn
    • Primary Myelofibrosis
    • +4 more
    • (no location specified)
    2021-03-02
    Mar 2, 2021
    U
    Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
    Not yet recruiting
    • Myeloproliferative Neoplasm
    • +3 more
    • CALR allele burden quantification
    • (no location specified)
    2021-06-18
    Jun 18, 2021
    N
    Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
    Not yet recruiting
    • Primary Myelofibrosis
    • +2 more
    • (no location specified)
    2021-11-05
    Nov 5, 2021
    J
    MPN-RC 118 AVID200 in Myelofibrosis
    Active, not recruiting
    • Primary Myelofibrosis
    • +4 more
    • New York, New York
      Icahn School of Medicine at Mount Sinai
    2021-05-19
    May 19, 2021
    F
    The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line - 2021
    Terminated
    • Essential Thrombocythemia
    • Tours, France
      FILO
    2021-06-28
    Jun 28, 2021
    M
    Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
    Recruiting
    • Myelofibrosis Transformation in Essential Thrombocythemia
    • +2 more
    • Elotuzumab
    • Questionnaire Administration
    • Houston, Texas
      M D Anderson Cancer Center
    2021-02-17
    Feb 17, 2021
    I
    IMG-7289 in Patients With Myelofibrosis - 2022
    Completed
    • Myelofibrosis
    • +3 more
    • Ann Arbor, Michigan
    • +4 more
    2022-03-28
    Mar 28, 2022
    M
    Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
    Recruiting
    • Acute Myeloid Leukemia
    • +15 more
    • Houston, Texas
      M D Anderson Cancer Center
    2021-03-09
    Mar 9, 2021
    S
    The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) - 2008
    Completed
    Has Results
    • Essential Thrombocythaemia
    • anagrelide hydrochloride
    • Barcelona, Spain
    • +4 more
    2021-06-07
    Jun 7, 2021
    D
    Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure - 2020
    Completed
    • Polycythemia Vera
    • Thrombocythemia, Essential
    • No cytoreductive vs cytoreductive drugs
    • Geneva, Switzerland
    • +1 more
    2020-11-09
    Nov 9, 2020
    M
    Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
    Recruiting
    • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    2021-10-30
    Oct 30, 2021